Peggy Thompson

Peggy Thompson, PhD is the Vice President of Biology and leads the targeted protein degradation drug discovery efforts at Plexium. She joined Plexium in 2020, with more than 20 years of experience in drug discovery and development in the biotechnology industry. Prior to Plexium, Peggy was a co-founder and Executive Director of Biology at eFFECTOR Therapeutics where she established their technology platform for targeting dysregulated mRNA translation for supporting oncology drug development and lead their eIF4A program (Zotatifin) from concept to clinical development in solid tumor malignancies. She previously served as Director of Biology at Anadys Pharmaceuticals, Inc. and held positions of increasing responsibility during her tenure until the company was acquired by Roche Pharmaceuticals. Prior to Anadys, Dr. Thompson held positions at Biopraxis and the National Institutes of Health. She was an NIH postdoctoral fellow in Biophysics at the University of California, Berkeley and completed her Ph.D. in Chemistry from the University of California, San Diego. She received her B.S. in Biochemistry with Highest Distinction from Washington State University.